Budapest II

• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une … Ended recruitment
  2024-513460-26-00 5 2023-03-29 Refractory Chronic Cough, Including Unexplained Chronic Cough
• "Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Children with Partial-onset (Focal) Seizures " Ended recruitment
  2023-506841-52-00 5 2023-03-22 partial-onset (focal) seizures
• A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic … Ended recruitment
  2023-510019-20-00 5 2022-07-13 Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter
• A clinical study to assess the efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirr … Ended recruitment
  2023-508248-23-00 5 2021-11-26 Non-alcoholic steatohepatitis (NASH)
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic … Ended recruitment
  2023-506256-25-00 5 2021-10-20 Active Psoriatic Arthritis
• Guselkumab versus Placebo for the Treatment of Active Psoriatic Arthritis in Participants with Inadequate Response and/or Intolerance to One … Ended recruitment
  2023-504715-33-00 5 2021-09-27 Psoriatic Arthritis
• A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended recruitment
  2023-504734-21-00 5 2021-08-30 Psoriatic arthritis (PsA)
• Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Ended recruitment
  2023-504716-15-00 6 2021-08-06 Psoriatic Arthritis
• Efficacy and Safety of Erenumab in Pediatric Subjects with Episodic Migraine Ended recruitment
  2023-504930-23-00 5 2019-07-19 Episodic Migraine
• A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Respo … Ended recruitment
  2023-505477-33-00 5 2019-06-18 Psoriatic Arthritis
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth … Ended recruitment
  2022-501017-31-00 5 2016-05-10 Rheumatoid arthritis
• A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended
  2023-507705-34-00 5 2025-08-29 Moderate to Severe Active Ulcerative Colitis
• A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in … Ended
  2024-510826-16-00 5 2025-04-07 Rheumatoid Arthritis
• A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi … Ended
  2023-506664-14-00 5 2024-10-24 Rheumatoid Arthritis
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to … Ended
  2023-504564-42-00 4 2024-04-08 Moderate to Severe Rheumatoid Arthritis
• A study to investigate the effect of different doses of AZD0780 on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo … Ended
  2023-506197-12-00 4 2024-02-07 Dyslipidemia Dyslipidemias are alterations to the plasma lipid profile
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• Study of efficacy and safety of secukinumab in participants with moderate-severe rotator cuff tendinopathy Ended
  2022-502080-38-00 5 2023-10-16 Moderate to severe rotator cuff tendinopathy
• BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous Urticaria Ended
  2024-514764-72-00 5 2023-09-27 Chronic Urticaria
• A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a … Ended
  2022-501895-25-00 5 2023-09-13 Polymyalgia Rheumatica
• An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis Ended
  2022-502994-40-00 4 2023-09-04 Rheumatoid Arthritis
• Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended
  2023-506046-24-00 4 2023-07-03 Ulcerative Colitis (UC)

Showing 49–72 of 83 trials